NCT04844840View on ClinicalTrials.gov

A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

May 17, 2023

Study Completion Date

May 17, 2023

Conditions
Keloid
Interventions
DRUG

STP705

STP705 is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA, respectively

OTHER

Placebo

Saline

Trial Locations (3)

33180

Center for Clinical and Cosmetic Research, Aventura

85255

Investigate MD, Scottsdale

07601

Schweiger Dermatology, Hackensack

Sponsors

Lead Sponsor

Sirnaomics
All Listed Sponsors
lead

Sirnaomics

INDUSTRY

NCT04844840 - A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence | Biotech Hunter | Biotech Hunter